CRS + HIPEC
Patient diagnosed with Stage IIIC high-grade serous carcinoma of the ovary (extensive peritoneal dissemination with multivisceral involvement)
RAND
Mission
Serving patients with high technology products to achieve significant improvement for their health.
About us
Located in the internationally well-known Mirandola Bio-medical district, RanD is a knowledge-based company, established in 1999 exploiting more than 30 years’ experience in the bio-medical field.
The name RanD originates from the phonetic transcription of the English acronym R&D (Research and Development) direct expression of RanD core activity: the development of technologically innovative systems based on extracorporeal circulation technologies, marked, at the same time, by extremely simplified operative management.
Over the years RanD developed a whole range of products mainly focused on surgical oncology, but it also exploited its own know-how in the development of third-party cutting-edge projects in the fields of liver support, cardiopulmonary support and dialysis.
RanD directly handles the whole manufacturing cycles of equipment and disposable devices, thus ensuring highest quality standards for each manufacturing phase.
CRS + HIPEC in Recurrent Ovarian Cancer
Case Record: CRS+HIPEC for recurrent Epithelial Ovarian Cancer (EOC). Clinical History. Patient #1: · Patient diagnosed with recurrent EOC (sensitive to platinum). Histology: mucinous tumor. Endocervical type · Clinical, biochemical, and radiological response. · Cytoreductive Radical Surgery plus Heated Intraperitoneal Chemotherapy (CRS + HIPEC) is proposed Other History: The radiological study was given at the diagnosis of the recurrence and the neoadjuvant CT treatment was finished Technique Description 1) Xiphopubic approach to the abdomen 2) Rigorous exploration of all abdominal-pelvic regions 3) Confirmation of the technical possibilities of complete cytoreduction with absence of visible tumor residue (CC-O) 4) Strategic design of the CRS by unifying all the peritonectomy procedures described by Sugarbaker in two surgical steps 5) Confirmation of the CC-O 6) Administration of the HIPEC in the open mode (Colosseum) Procedure Steps 1) Parietal peritonectomy, pelvic peritonectomy with rectosigmoid resection 2) Residual greater omentectomy, and splenectomy 3) Subphrenic right peritonectomy and lesser omentectomy 4) Digestive reconstruction. Colo-rectal anastomosis without stoma 5) "Colosseum" HIPEC: preparation and administration. Preparation and administration of chemotherapy for 60 min at 42.5ºC Learning Points · Role of CRS + HIPEC in recurrent EOC ovarian cancer · Use of Peritonectomy Procedures associated with visceral resection (Sugarbaker) to achieve complete CRS (macroscopic absence of tumor CC-O) · Technical modifications to the original peritonectomy procedures · Pelvic peritonectomy and rectosigmoid colon resection · Greater (residual) omentectomy and splenectomy · Left subphrenic peritonectomy · Lesser omentectomy and cholecystectomy with stripping of the hepatoduodenal ligament · Complete right subphrenic peritonectomy · “True” end to end colorectal mechanical reinforced anastomosis · Preparation and administration of the HIPEC in its “open” or coliseum modality · Personal series results. 146 patients treated for recurrent EOC over 1.240 CRS+HIPEC · Conclusions
IN ALLIANCE WITH
.jpg)
